Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Inventory Average (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Inventory Average for 8 consecutive years, with $69.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory Average rose 34.01% year-over-year to $69.1 million, compared with a TTM value of $69.1 million through Dec 2025, up 34.01%, and an annual FY2025 reading of $63.2 million, up 32.08% over the prior year.
  • Inventory Average was $69.1 million for Q4 2025 at Neurocrine Biosciences, up from $63.1 million in the prior quarter.
  • Across five years, Inventory Average topped out at $69.1 million in Q4 2025 and bottomed at $26.9 million in Q3 2021.
  • Average Inventory Average over 4 years is $39.3 million, with a median of $32.6 million recorded in 2023.
  • Peak annual rise in Inventory Average hit 81.57% in 2021, while the deepest fall reached 26.29% in 2021.
  • Year by year, Inventory Average stood at $26.9 million in 2021, then increased by 24.72% to $33.6 million in 2023, then soared by 53.8% to $51.6 million in 2024, then surged by 34.01% to $69.1 million in 2025.
  • Business Quant data shows Inventory Average for NBIX at $69.1 million in Q4 2025, $63.1 million in Q3 2025, and $51.6 million in Q4 2024.